News und Analysen
NanoString Technologies Announces Pricing of Upsized Offering of $200 Million of Convertible Senior Notes
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for translational research, today announced the pricing of $200 million aggregate principal amount of 2.625%
Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2019 Financial Results
Regulatory News:
Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on
Cellectis and Servier Execute the Amendment Confirming the Expansion of Their Collaboration on UCART19 Products
Regulatory News:
Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on
Charles River Laboratories Adds Nancy C. Andrews, M.D., Ph.D., to Board of Directors
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the appointment of Nancy C. Andrews, M.D., Ph.D., to its Board of Directors, effective February 28, 2020. Dr. Andrews is
Navidea Biopharmaceuticals to Host Fourth Quarter 2019 Earnings Conference Call and Corporate Update
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Susan Hockfield Elected to Pfizer’s Board of Directors
Pfizer Inc. (NYSE: PFE) today announced the election of Dr. Susan Hockfield to its Board of Directors, effective immediately. Dr. Hockfield, age 68, was also appointed to the Regulatory and
NanoString Technologies Announces Proposed Private Offering of $175 Million of Convertible Senior Notes
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for translational research, today announced that it intends to offer, subject to market conditions and other
Veeva Announces Fiscal 2020 Fourth Quarter and Fiscal Year 2020 Results
Veeva Systems Inc. (NYSE: VEEV), a leading provider of industry cloud solutions for the global life sciences industry, today announced results for its fiscal fourth quarter ended January 31, 2020
Biofrontera: Kleiner, aber feiner Geldregen
Die Biofrontera-Aktie (WKN: 604611) gehört am Dienstag zu den stärksten Werten. Im Xetra-Handel schließt der Kurs +16,10% höher bei 4,65 Euro. Das hat einen guten Grund.
Das Biopharma-Unternehmen
Mauna Kea Technologies Receives FDA Clearance And CE Marking For Its Next-Generation Cellvizio® Platform
Regulatory News:
Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary probe- and needle-based confocal laser endomicroscopy (pCLE/nCLE)
Qiagen: Heiße Übernahme-Wette geht auf
Ungeahnte Freudensprünge bei Qiagen (WKN: A2DKCH): Weil jetzt doch noch ein Übernahmeangebot kommt, gewinnt die Aktie heute um rund 18 Prozent auf 37,5 Euro – der größte Tageszuwachs seit zwei
ICON plc to Present at Barclays Global Healthcare Conference 2020
ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, today announced that Mr
Clovis Oncology to Present at the Barclays Global Healthcare Conference
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its President and Chief Executive Officer, Patrick J. Mahaffy, will present at the Barclays Global Healthcare Conference on Tuesday, March
Agilent Introduces Three New Microarrays for Prenatal and Postnatal Research
Agilent Technologies Inc. (NYSE: A) today introduced three new microarrays to meet the needs of cytogenetic laboratories conducting both prenatal and postnatal research.
The new Agilent
Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year 2019 Financial Results on March 5, 2020
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that it will release its fourth quarter and full year 2019 financial results on Thursday, March 5, 2020, after
Transgene and BioInvent to Present Data on BT-001, an Oncolytic Virus Encoding for an Anti-CTLA4 Antibody, at Upcoming Congresses
Regulatory News:
Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent International AB
GenSight Biologics Announces Presentation of Bilateral Visual Recovery From GS010 (LUMEVOQ™) Phase III Trials at the 46th Annual Meeting of NANOS
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for
Vifor Pharma Secures a Second Investment Grade Rating From Fitch Ratings
Regulatory News:
Vifor Pharma today announced that Fitch Ratings (Fitch) has initiated coverage of Vifor Pharma with an investment grade BBB- credit rating and a stable outlook. This investment
Takeda schließt Verkauf ausgewählter OTC- und nicht zum Kerngeschäft gehörender Assets an Acino ab
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) („Takeda“) meldete heute den Abschluss des bereits angekündigten Verkaufs eines Portfolios ausgewählter, frei verkäuflicher
Premier Inc. Survey Finds 86 Percent of Health Systems Are Concerned About Personal Protective Equipment Shortages Due to Coronavirus
Premier Inc. (NASDAQ: PINC) today released survey results finding that 86 percent of U.S. hospitals and health systems are concerned about their supply of face masks and other personal protective
Heat Biologics mit +210% in 2 Tagen – dank Corona!
Als einer der meistdiskutierten Werte in unserem Live Chat macht die Aktie von Heat Biologics (WKN: A2JB4Y) aktuell mit einem Höhenflug von +210% innerhalb von nur zwei Tagen auf sich aufmerksam
Takeda vereinbart Veräußerung ausgewählter kernferner und OTC-Aktiva in Lateinamerika an Hypera Pharma für 825 Mio. USD
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) („Takeda“) hat eine Vereinbarung darüber geschlossen, ein Portfolio ausgewählter kernferner Produkte ausschließlich für den
Agilent and Visiopharm Co-promote Advanced Digital Precision Pathology Solutions
Agilent Technologies Inc. (NYSE: A) and Visiopharm today announced that they have entered a co-marketing agreement. The announcement is happening at the USCAP 109th Annual Meeting being held
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the following investor conferences:
-
Cowen 40th Annual Health Care